Since our CI experts are highly proficient in conducting surveillance and are already on the cutting-edge of knowledge in their cancer areas, they can run extensive searches and are adept at discerning what new scientific, clinical and market events impact their landscapes and can provide intelligent insight to clients about the future marketplace.
Our analysts vigilantly monitor multiple secondary and primary sources to comprehensively cover clinical trials, product developments, company activities, and regulatory news to deliver monthly reports with unparalleled CI value.
ONCrg specialists vigilantly monitor scientific, clinical and commercial developments via multiple secondary and primary sources to provide expert CI support year-round with succinct but comprehensive analyses of market changes and new data releases.
Our comprehensive coverage of clinical trials include a brief write up about estimated completion date changes, significant enrollment changes, and clinical trials on hold or terminated and why. More detailed analysis and insights are provided for new and completed clinical trials Ph I/II and greater.
We look for information that is scientifically and clinically relevant to our pipelines (all drugs in Phase I/II development and beyond), whether it is regulatory news, product news, company news, or clinical trial news.
Our analysis of company news includes coverage of research, development and marketing collaborations, alliances, mergers, acquisitions, IPOs and major funding activities, and other major commercial developments in oncology.
Our analysis of regulatory news includes coverage of FDA approvals, breakthrough therapy designations, Orphan Drug designations, BLA submissions, as well as European Commission, NICE and other major regional activities.
Click your area of interest for a Sample of our Sentinel report